DAIICHI-SANKYO-DS3201-343
Phase I
OPEN TO ACCRUAL
A Phase 1, Multicenter Trial Evaluating the Safety, Tolerability, and Efficacy of Valemetostat (DS-3201) in Combination with Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)
DAIICHI-SANKYO-DS3939-077
Phase I/II
OPEN TO ACCRUAL
A Phase 1/2, Open-Label, Multicenter, First-in-Human Study of DS-3939a in Subjects with Advanced Solid Tumors
IIT-GORE-REDIRICT
Phase II
OPEN TO ACCRUAL
High Dose Re-Irradiation Utilizing Advanced Deformable Image Registration (DIR) and Individualized Organ At Risk (OAR) Dose Calculations with Organ Specific Toxicity Analysis (Re-DIRICT)
IIT-HALL-MRI-ENHANCE
Phase I
OPEN TO ACCRUAL
MRI-Guided Adaptive Radiation Therapy for Organ Preservation in Rectal Cancer
NEOGENE-NT-112-301
Phase I
OPEN TO ACCRUAL
An Open-Label, Phase 1, Multi-Center Study to Evaluate the Safety and Preliminary Anti-Tumor Activity of NT-112 in Human Leukocyte Antigen-C*08:02-Positive Adult Subjects with Unresectable, Advanced and/or Metastatic Solid Tumors That Are Positive for the KRAS G12D Mutation
NEOGENE-NT-175-201
Phase I
OPEN TO ACCRUAL
An Open-Label, Phase 1, Multicenter Study to Evaluate the Safety and Preliminary Anti-Tumor Activity of NT-175 in Human Leukocyte Antigen-A*02:01-Positive Adult Subjects with Unresectable, Advanced and or Metastatic Solid Tumors That Are Positive for the TP53 R175H Mutation
STEMLINE-MEN2312-01
Phase I
OPEN TO ACCRUAL
A Phase 1, First-in-Human Study of MEN2312, a KAT6 Inhibitor, as Monotherapy and in Combination in Participants with Advanced Breast Cancer
TERREMOTO-TER-2013-C01
Phase I/II
OPEN TO ACCRUAL
A Phase 1/2 Trial of TER-2013 in Patients with Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
TEVA-TV56278-ONC-10203
Phase I
OPEN TO ACCRUAL
A Phase 1a/1b Open-Label, Multicenter, Dose Escalation, and Dose Expansion Trial to Evaluate the Safety and Activity of TEV-56278, as a Monotherapy and in Combination with Pembrolizumab in Participants with Selected Locally Advanced or Metastatic Solid Tumors